|
|
Blood, 15 January 2004, Vol. 103, No. 2, pp. 442-450.
Prepublished online as a Blood First Edition Paper on September 22, 2003; DOI 10.1182/blood-2003-05-1495.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951
Hélène Cavé,
Stefan Suciu,
Claude Preudhomme,
Bruce Poppe,
Alain Robert,
Anne Uyttebroeck,
Michèle Malet,
Patrick Boutard,
Yves Benoit,
Laurent Mauvieux,
Patrick Lutz,
Françoise Méchinaud,
Nathalie Grardel,
Françoise Mazingue,
Madeleine Dupont,
Geneviève Margueritte,
Marie-Pierre Pages,
Yves Bertrand,
Emmanuel Plouvier,
Ghislaine Brunie,
Christian Bastard,
Dominique Plantaz,
Isabel Vande Velde,
Anne Hagemeijer,
Frank Speleman,
Michel Lessard,
Jacques Otten,
Etienne Vilmer, and
Nicole Dastugue, the EORTC-CLG
From the Laboratoire de Biochimie Génétique, Hôpital Robert Debré (Assistance Publique-Hôpitaux de Paris [AP-HP]), Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U417, Hôpital Robert Debré, Paris, France; European Organization for Research and Treatment of Cancer (EORTC) Data Center, Brussels, Belgium; Laboratoire d'Hématologie A, Hôpital Calmette, Lille, France; Universitair Ziekenhuis Ghent, Ghent, Belgium; Unité d'Hématologie Infantile, Hôpital Purpan, Toulouse, France; U. Z. Gasthuisberg, Leuven, Belgium; Unité d'Onco-Hématologie Pédiatrique, Centre Hospitalier Universitaire (CHU), Caen, France; Hôpital Universitaire Hautepierre, Strasbourg, France; CHR Hôtel Dieu, Nantes, France; CHR de Lille, Lille, France; Hôpital Arnaud de Villeneuve, Montpellier, France; Hôpital Debrousse, Lyon, France; CHR de Besançon-Hôpital Saint Jacques, Besançon, France; Centre Henri Becquerel, Rouen, France; CHU de Grenoble, La Tronche, France; Akademisch Ziekenhuis - Vrije Universiteit Brussel (VUB), Brussels, Belgium; Service d'Immuno-Hématologie Pédiatrique, Hôpital Robert Debré (AP-HP), Paris, France; and Laboratoire d'Hématologie, Hôpital Purpan, Toulouse, France.
In a series of 153 children with T-cell malignancies enrolled in 2 consecutive European Organization for Research and Treatment of Cancer (EORTC) trials, we assessed the HOX11L2 expression and/or the presence of a t(5;14)(q35;q32). Additionally, in 138 of these patients, HOX11 expression and SIL-TAL rearrangement were also assessed. These alterations were mutually exclusive, and their frequency was 23% (n = 35), 7% (n = 10), and 12% (n = 17), respectively. HOX11L2/t(5;14) positivity was more frequent in acute lymphoblastic leukemia (ALL) with cortical T immunophenotype and in children aged between 6 and 9 years. In contrast with previously reported data, patients positive and negative for HOX11L2/t(5;14) were comparable with regard to clinical outcome as well as to the response to a 7-day prephase treatment or to residual disease at completion of induction therapy. The 3-year event-free survival (EFS) rate (± SE percentage) for patients positive and negative for HOX11L2/t(5;14) was 75.5% (± 8.1%) and 68.3% (± 5.0%), respectively; the hazard ratio was 0.84 (95% confidence interval, 0.40-1.80). Patients with HOX11-high expression and those with SIL-TAL fusion had low levels of residual disease at the end of induction and a favorable prognosis: the 3-year EFS rate was 83.3% (± 8.5%) and 75.3% (± 12.6%), respectively. The results obtained in HOX11L2/t(5;14) patients in this study do not confirm the unfavorable prognosis reported in previous studies.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Ballerini, J. Landman-Parker, J. M. Cayuela, V. Asnafi, M. Labopin, V. Gandemer, Y. Perel, G. Michel, T. Leblanc, C. Schmitt, et al.
Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome
Haematologica,
November 1, 2008;
93(11):
1658 - 1665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Baleydier, A.-V. Decouvelaere, J. Bergeron, P. Gaulard, D. Canioni, Y. Bertrand, S. Lepretre, B. Petit, H. Dombret, K. Beldjord, et al.
T Cell Receptor Genotyping and HOXA/TLX1 Expression Define Three T Lymphoblastic Lymphoma Subsets which Might Affect Clinical Outcome
Clin. Cancer Res.,
February 1, 2008;
14(3):
692 - 700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Bergeron, E. Clappier, I. Radford, A. Buzyn, C. Millien, G. Soler, P. Ballerini, X. Thomas, J. Soulier, H. Dombret, et al.
Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs
Blood,
October 1, 2007;
110(7):
2324 - 2330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-Y. Su, V. Della-Valle, I. Andre-Schmutz, C. Lemercier, I. Radford-Weiss, P. Ballerini, M. Lessard, M. Lafage-Pochitaloff, F. Mugneret, R. Berger, et al.
HOX11L2/TLX3 is transcriptionally activated through T-cell regulatory elements downstream of BCL11B as a result of the t(5;14)(q35;q32)
Blood,
December 15, 2006;
108(13):
4198 - 4201.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Baldus, T. Burmeister, P. Martus, S. Schwartz, N. Gokbuget, C. D. Bloomfield, D. Hoelzer, E. Thiel, and W. K. Hofmann
High Expression of the ETS Transcription Factor ERG Predicts Adverse Outcome in Acute T-Lymphoblastic Leukemia in Adults
J. Clin. Oncol.,
October 10, 2006;
24(29):
4714 - 4720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Borghini, M. Vargiolu, M. Di Duca, R. Ravazzolo, and I. Ceccherini
Nuclear Factor Y Drives Basal Transcription of the Human TLX3, a Gene Overexpressed in T-Cell Acute Lymphocytic Leukemia
Mol. Cancer Res.,
September 1, 2006;
4(9):
635 - 643.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-M. Zhu, W.-L. Zhao, J.-F. Fu, J.-Y. Shi, Q. Pan, J. Hu, X.-D. Gao, B. Chen, J.-M. Li, S.-M. Xiong, et al.
NOTCH1 Mutations in T-Cell Acute Lymphoblastic Leukemia: Prognostic Significance and Implication in Multifactorial Leukemogenesis.
Clin. Cancer Res.,
May 15, 2006;
12(10):
3043 - 3049.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Peyriere, E. Jeziorsky, A. Jalabert, M. Cociglio, A. Benketira, J.-P. Blayac, S. Hansel, G. Margueritte, and D. Hillaire-Buys
Neurotoxicity Related to Valganciclovir in a Child with Impaired Renal Function: Usefulness of Therapeutic Drug Monitoring
Ann. Pharmacother.,
January 1, 2006;
40(1):
143 - 146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Armstrong and A. T. Look
Molecular Genetics of Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
September 10, 2005;
23(26):
6306 - 6315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Asnafi, A. Buzyn, X. Thomas, F. Huguet, N. Vey, J.-M. Boiron, O. Reman, J.-M. Cayuela, V. Lheritier, J.-P. Vernant, et al.
Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study
Blood,
April 15, 2005;
105(8):
3072 - 3078.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Asnafi, K. Beldjord, M. Libura, P. Villarese, C. Millien, P. Ballerini, E. Kuhlein, M. Lafage-Pochitaloff, E. Delabesse, O. Bernard, et al.
Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy
Blood,
December 15, 2004;
104(13):
4173 - 4180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui, M. V. Relling, and J. R. Downing
Acute Lymphoblastic Leukemia
N. Engl. J. Med.,
April 8, 2004;
350(15):
1535 - 1548.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui, M. Schrappe, R. C. Ribeiro, and C. M. Niemeyer
Childhood and Adolescent Lymphoid and Myeloid Leukemia
Hematology,
January 1, 2004;
2004(1):
118 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
